InSite Vision Announces Positive Phase 3 Results for BromSite

by CRST • 2013/04/02 • 0 Comments

BromSite (ISV-303; InSite Vision Inc.) achieved statistically significant superiority compared with DuraSite (InSite Vision Inc.) alone in alleviating ocular pain and inflammation after cataract surgery in a phase 3 clinical trial, according to a company news release. BromSite combines a low dose (0.075%) of the nonste...

← OIG’s strong language on physician-owned distributorships is clear message to investors

Central retinal vessel trunk position affects visual field pattern in advanced glaucoma →

Post navigation